SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Somatogen (SMTG)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bharat H. Barai who wrote (331)12/3/1997 10:43:00 PM
From: Timothy Kross  Read Replies (1) of 442
 
Dr. Barai: I want to thank you for your posts and prior responses to my postings. I have been slowly accululating SMTG at these prices ($5.50 - $6.00). Certainly risk is involved here but in the long run I believe that the risk will pay off.

It is reassuring to see how Eli Lilly has certainly made some bad judgments already that add up to billions of dollars. These include the backing away from the Viracept/Agouron venture, as well as the Guidant and the McKesson fiascos.

Remembering what John Templeton said, basically was that to make money in the stock market one had to buy when nobody wanted the stock then graciously stand aside and sell when the stampede develops. I do not presume to know the final story on OPTRO or SMTG, but I have faith in their ideas.

Going through the MTSL website, it is clear that Jim McCamant is also very high on SMTG.

Best regards,

TJK.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News